Daily Endocrinology Research Analysis
Analyzed 75 papers and selected 3 impactful papers.
Summary
Three high-impact studies reshape endocrine-metabolic thinking this cycle: human chronometabolic profiling identifies nighttime metabolic dysfunction as a hallmark of MASLD; mechanistic work reveals how prior hypoglycemia impairs counter-regulatory glucagon via δ-cell somatostatin feedback; and a large SPRINT cohort analysis shows that combining prediabetes status with cardiac biomarkers markedly improves heart failure risk stratification in hypertension.
Research Themes
- Chronometabolism and diurnal regulation in MASLD
- Intra-islet paracrine control of glucagon after hypoglycemia
- Integrated biomarker-based heart failure risk stratification in dysglycemia
Selected Articles
1. Human MASLD is a diurnal disease driven by multisystem insulin resistance and reduced insulin availability at night.
In human MASLD, nighttime metabolic dysfunction is pronounced: hepatic and peripheral insulin resistance, de novo lipogenesis, and NEFA exposure increase at night while plasma insulin availability falls due to both reduced secretion and increased clearance. These diurnal abnormalities persist even after weight-loss–induced reductions in liver fat, and multi-tissue proteomics highlight candidate targets. Findings support chrono-nutrition/exercise and time-of-day medication strategies.
Impact: This is the first human study to map diurnal metabolic fluxes in MASLD with isotope tracers, revealing nighttime as a key pathogenic window and providing a rationale for chronotherapy.
Clinical Implications: Counsel MASLD patients to concentrate energy intake earlier in the day, prioritize evening insulin-sensitizing activity, and consider time-of-day dosing of agents affecting DNL or insulin dynamics (e.g., GLP-1RA, SGLT2i, pioglitazone) pending trials.
Key Findings
- Nighttime hepatic and peripheral insulin resistance, de novo lipogenesis, and systemic NEFA exposure are elevated in MASLD.
- Plasma insulin availability is lower at night due to reduced secretion and increased clearance.
- Diurnal metabolic differences persist after weight loss with reduced liver fat, implicating chronobiology as a primary driver.
- Integrated proteomics across plasma, adipose, and muscle identified candidate molecular targets varying by time-of-day.
Methodological Strengths
- State-of-the-art stable isotope tracer methodologies with within-subject day–night phenotyping
- Integrated multi-tissue proteomics enhancing mechanistic interpretation
Limitations
- Sample size and cohort breadth not specified in the abstract; generalizability requires confirmation
- Observational day–night design without interventional chronotherapy testing limits causal inference for timing strategies
Future Directions: Randomized chronotherapy trials in MASLD to test time-of-day-specific nutrition, exercise, and pharmacotherapy; validation in diverse populations and integration with wearable circadian metrics.
Hepatic lipid and glucose metabolism have been shown to be under tight circadian control in pre-clinical models. However, it remains unknown whether diurnal patterns exist in functional processes governing intrahepatic lipid accumulation in humans. We performed metabolic phenotyping, including state-of-the-art stable isotope techniques, during day and night in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and overweight controls (NCT05962099). The primary outcome was diurnal chang
2. Antecedent hypoglycaemia impairs glucagon secretion by enhancing somatostatin-mediated negative feedback control.
α-cell-derived glutamate and glucagon co-activate δ-cells via AMPA and glucagon receptors to establish somatostatin feedback that restrains glucagon. Antecedent hypoglycemia sensitizes δ-cells and induces durable structural/functional changes, causing somatostatin hypersecretion and impaired counter-regulatory glucagon. Blocking glucagon receptors or CREB prevents these effects; α-cell chemogenetic activation or high glucagon mimics them.
Impact: It uncovers a concrete intra-islet circuit by which hypoglycemia history impairs glucagon counter-regulation, offering mechanistic targets (glucagon receptor/CREB/δ-cell signaling) to reduce recurrent hypoglycemia in insulin-treated diabetes.
Clinical Implications: Therapeutic strategies targeting δ-cell signaling or glucagon receptor pathways may restore counter-regulatory glucagon responses and reduce recurrent hypoglycemia risk in insulin-dependent diabetes.
Key Findings
- α-cell glutamate and glucagon co-activate δ-cells via AMPA and glucagon receptors to control glucagon via somatostatin feedback.
- Antecedent hypoglycemia sensitizes δ-cells, causing somatostatin hypersecretion and impaired counter-regulatory glucagon.
- Effects are mimicked by α-cell chemogenetic activation or high glucagon and prevented by glucagon receptor or CREB inhibition.
Methodological Strengths
- Multi-system mechanistic approach combining electrophysiology, chemogenetics, and receptor pharmacology
- Clear causal testing of receptor pathways (AMPA, glucagon receptor) and transcriptional mediator (CREB)
Limitations
- Preclinical models predominate; translational validation in human islets and clinical settings is needed
- Long-term reversibility of δ-cell sensitization after hypoglycemia remains to be established
Future Directions: Test δ-cell or glucagon receptor–targeted agents to restore counter-regulation in humans; longitudinal studies linking hypoglycemia exposure with δ-cell plasticity markers in vivo.
Somatostatin, produced by pancreatic islet δ cells, is a key intra-islet paracrine factor that regulates the secretion of the glucoregulatory hormones insulin and glucagon from β cells and α cells, respectively. Here, we show that glutamate and glucagon released by α cells cooperatively activate neighbouring δ cells through AMPA and glucagon receptors, thereby enabling spatiotemporal feedback control of glucagon secretion. Crucially, prior hypoglycaemia enhances this mechanism by sensitizing δ cells to α cell-
3. Prediabetes, Subclinical Myocardial Injury or Stress, and Heart Failure Risk for Adults With Hypertension.
Among 8,234 hypertensive SPRINT participants without diabetes or prior HF, prediabetes combined with elevated hs-cTnI or NT-proBNP conferred the highest HF risk (HR 4.20 and 5.20, respectively). Longitudinal 25% increases in these biomarkers at 12 months further identified those at greatest risk. Integrating glycemic status with cardiac biomarker profiling may improve HF risk stratification and prevention.
Impact: Large, adjudicated cohort data demonstrate that combining dysglycemia with subclinical cardiac injury/stress markers sharply enhances HF risk prediction in hypertension, supporting biomarker-guided prevention.
Clinical Implications: In hypertensive adults, consider adding hs-cTnI and/or NT-proBNP to routine labs, especially when fasting glucose is in the prediabetes range, to identify candidates for intensified HF prevention (aggressive BP control, SGLT2i consideration, lifestyle).
Key Findings
- Prediabetes plus elevated hs-cTnI was associated with markedly higher HF risk (HR 4.20; 95% CI, 2.31–7.63).
- Prediabetes plus elevated NT-proBNP conferred similarly high HF risk (HR 5.20; 95% CI, 2.52–10.70).
- A ≥25% increase in hs-cTnI or NT-proBNP over 12 months identified participants at highest subsequent HF risk.
Methodological Strengths
- Large, well-characterized hypertensive cohort with adjudicated HF outcomes
- Time-updated biomarker assessment and multivariable Cox modeling
Limitations
- Post hoc analysis within SPRINT; generalizability limited to non-diabetic hypertensive adults under trial conditions
- Prediabetes defined by fasting glucose alone (no HbA1c/OGTT), and relatively few HF events
Future Directions: Prospective validation of combined glycemic–cardiac biomarker algorithms and testing biomarker-guided intensified prevention strategies in diverse hypertensive populations.
IMPORTANCE: It is unclear whether and the extent to which subclinical myocardial injury or stress coexisting with prediabetes is associated with the risk of heart failure (HF). OBJECTIVE: To evaluate the joint associations of prediabetes and subclinical myocardial injury or stress with incident HF risk. DESIGN, SETTING, AND PARTICIPANTS: This post hoc prospective cohort study analyzed data from the Systolic Blood Pressure Intervention Trial (SPRINT). Two analytic samples were used: (1) adults with hyperten